Xeris Biopharma Holdings (XERS) Cost of Revenue (2020 - 2026)

Xeris Biopharma Holdings has reported Cost of Revenue for 7 years, with the latest figure at $10.6 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue rose 21.15% year-over-year to $10.6 million; the trailing twelve-month figure through Mar 2026 stood at $44.4 million (up 12.19% YoY), and the FY2025 full-year result was $42.6 million, up 15.58% from the prior year.
• Cost of Revenue for Q1 2026 stood at $10.6 million, down from $10.9 million in the prior quarter.
• The five-year high for Cost of Revenue was $13.6 million in Q3 2024, with the low at $4.8 million in Q2 2022.
• Historically, Cost of Revenue has averaged $8.3 million across 5 years, with a median of $7.8 million in 2024.
• Annual changes were most pronounced in 2022 — Cost of Revenue soared 243.54% — and 2025, when it retreated 19.11%.
• Xeris Biopharma Holdings' Cost of Revenue stood at $6.3 million in 2022, then advanced by 20.33% to $7.6 million in 2023, then gained by 25.2% to $9.5 million in 2024, then rose by 15.5% to $10.9 million in 2025, then fell by 3.41% to $10.6 million in 2026.
• The last three Cost of Revenue figures came in at $10.6 million (Q1 2026), $10.9 million (Q4 2025), and $11.0 million (Q3 2025), per Business Quant data.